Allianz Asset Management
MRNS

Allianz Asset Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Allianz Asset Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-18,309
Closed -$394K – 2629
2016
Q1 		$394K Sell
18,309
-1,047
-5% -$22.2K ﹤0.01% 2296
2015
Q4 		$592K Sell
19,356
-996
-5% -$29.2K ﹤0.01% 2146
2015
Q3 		$679K Buy
+20,352
New +$1.15M ﹤0.01% 1970

Other funds holding MRNS

CPV
Canaan Partners VII Westport, Connecticut $32.3M AUM 154.97% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Allianz Asset Management's MRNS Position: Q2 2016 in Review

Allianz Asset Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2016, closing a stake of 18,309 shares — an estimated $394K sold.

Allianz Asset Management first reported a position in MRNS in Q3 2015 and held it in 3 quarters. The position peaked at $679K in Q3 2015. 28 funds tracked by Wall St. Rank hold MRNS as of Q2 2016.

  • Allianz Asset Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2016 after selling out during the quarter.
  • Allianz Asset Management sold 18,309 Marinus Pharmaceuticals, Inc shares in Q2 2016, an estimated $394K.
  • Allianz Asset Management first reported a position in Marinus Pharmaceuticals, Inc in Q3 2015 and held it in 3 quarters.
  • Allianz Asset Management's Marinus Pharmaceuticals, Inc position peaked at $679K in Q3 2015.
  • 28 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2016.

Based on Allianz Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.